Relation Between Matrix Gla Protein and Cardiac Vavular Calcifications in Haemodialysis Patients

Abstract

Heart valve calcification was first described a century ago. Its pathologic features were first described by Dewitsky in 1910. Valvular heart disease is common in end-stage renal disease patients. The incidence of valvular heart disease is 5 times greater in dialysis patients than in the general population MGP plays a key role in the inhibition of tissue calcification, which was demonstrated in MGP-deficient mice The aim of this Cross sectional observational study was to detect the prevalence of cardiac valvular calcifications among 80 end stage renal disease patients on prevalent haemodialysis and its relation to Matirx Gla protein (uncarboxylated form) divided into two groups as follows: group A included patients with valvular calcifications and group B included patients without valvular calcifications. Our results showed that, In current study, 19 (23.8%) patients showed mitral calcification, 30 (37.5%) showed aortic calcification and 44 (55.0%) had calcification in general as 5 patients had both mitral and aortic calcifications. In current study, the patient who had calcification were significantly older, heavier in weight and BMI and were had HD for longer than those who didn’t have calcification. Patient who had calcification had lower levels of both platelets and urea than those who didn’t have calcification.